36 Spam-Free Article(s) Found
https://www.zacks.com/stock/news/2252864/will-carlisle-csl-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2252864
Apr 09, 2024 - Carlisle (CSL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:2870443037855906767
0
https://www.zacks.com/stock/news/2257827/ge-aerospace-ge-gears-up-for-q1-earnings-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257827
Apr 18, 2024 - GE Aerospace's (GE) first-quarter results are likely to benefit from strength across its businesses. High costs and expenses might have been spoilsports.
zc:8775554153599086211
0
https://www.zacks.com/stock/news/2259311/analysts-estimate-lsb-lxu-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2259311
Apr 22, 2024 - LSB (LXU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-5854910273089117578
0
https://www.zacks.com/stock/news/2263283/carlisle-csl-q1-earnings-revenues-beat-estimates-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2263283
Apr 26, 2024 - Carlisle (CSL) first-quarter 2024 results benefit from higher revenues across the Carlisle Construction Materials segment.
zc:3862384876753318386
0
https://www.zacks.com/stock/news/2268048/itt-q1-earnings-revenues-beat-estimates-increase-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2268048
May 03, 2024 - ITT's Q1 revenues increase 14.1% year over year, driven by higher friction original equipment volumes in the Motion Technologies unit and volume growth in aerospace and defense components.
zc:7732543245089949253
0
https://www.zacks.com/stock/news/2274232/danaher-dhr-rides-on-business-strength-amid-headwinds?cid=CS-ZC-FT-analyst_blog|zer_report_update-2274232
May 15, 2024 - Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
zc:-6175523794720565745
0